Evaluation of renal exclusion criteria in early phase oncology trials: A call for modernization
European Journal of Cancer · 2026-06 · 242 · 116828
DOI: 10.1016/j.ejca.2026.116828 ↗Kurz gefasst
Leserbrief in der Zeitschrift European Journal of Cancer, 2026-06. Verfasst von Paul Matte und 4 weiteren Autor:innen. Beteiligte Einrichtung: Gustave Roussy, Drug Development Department, Villejuif, France; Groupe de Recherche Interdisciplinaire Francophone en Onco-néphrologie (GRIFON), Pari…. Die Arbeit nennt 11 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Gustave Roussy, Drug Development Department, Villejuif, France; Groupe de Recherche Interdisciplinaire Francophone en Onco-néphrologie (GRIFON), Paris, France.
- Gustave Roussy, Drug Development Department, Villejuif, France; Gustave Roussy, Department of Medical Oncology, Villejuif, France; Gustave Roussy, INSERM Unité 981, Université Paris-Saclay, Villejuif, France.
- Gustave Roussy, Drug Development Department, Villejuif, France.
- Gustave Roussy, Drug Development Department, Villejuif, France. Electronic address: matthieu.roulleaux-dugage@gustaveroussy.fr.
Zitieren
APA
Matte, P., Delaye, M., Loriot, Y., Massard, C., & Roulleaux Dugage, M. (2026). Evaluation of renal exclusion criteria in early phase oncology trials: A call for modernization. European Journal of Cancer, 242, 116828. https://doi.org/10.1016/j.ejca.2026.116828
Vancouver
Matte P, Delaye M, Loriot Y, Massard C, Roulleaux Dugage M. Evaluation of renal exclusion criteria in early phase oncology trials: A call for modernization. European Journal of Cancer. 2026;242:116828. doi:10.1016/j.ejca.2026.116828
BibTeX
@article{Matte2026,
author = {Matte, Paul and Delaye, Matthieu and Loriot, Yohann and Massard, Christophe and Roulleaux Dugage, Matthieu},
title = {Evaluation of renal exclusion criteria in early phase oncology trials: A call for modernization},
journal = {European Journal of Cancer},
year = {2026},
volume = {242},
pages = {116828},
doi = {10.1016/j.ejca.2026.116828}
}
EUVIMED